* Paves way for national vaccination campaign
* Have ordered 13 mln doses from Novartis, Glaxo
ZURICH, Oct 30 (Reuters) - Switzerland has approved two vaccines from GlaxoSmithKline (GSK.L) and Novartis NOVN.VX against H1N1 swine flu, regulators said on Friday, paving the way for a national immunisation campaign.
Switzerland has ordered 13 million doses of vaccine from Novartis and Glaxo, but will only start immunisations once the products are approved by Swissmedic.
Swissmedic approved Glaxo’s Pandemrix, but not for pregnant women, children under the age of 18 and adults over 60. Those over 60 can be inoculated with Pandemrix under recommendations from the Swiss Federal Office of Public Health (FOPH).
Novartis’s Focetria is recommended for use in adults and children over six months old. In the case of pregnant women and breastfeeding mothers, the attending doctor must weigh up the inoculation, in accordance with latest vaccine recommendations from the FOPH.
Swissmedic is still testing another Novartis vaccine, Celtura.
Drugmakers say they are on track to deliver as much H1N1 swine flu vaccine to the United States as they promised, in spite of concerns over production. [ID:nLT326192]
Analysts say Glaxo could book around 1 billion pounds ($1.7 billion) of this business in the fourth quarter as immunisation campaigns get underway. Novartis has said it expects a fourth-quarter sales boost of up to $700 million from its H1N1 pandemic vaccine. ($1=.6041 Pound) (Reporting by Sam Cage; editing by Simon Jessop)